<!--StartFragment-->RESULT 1
ADQ31356

SEQ ID No. 1

```
ID   ADQ31356 standard; protein; 123 AA.
XX
AC   ADQ31356;
XX
DT   07-OCT-2004  (first entry)
XX
DE   Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
XX
KW   Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW   allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
KW   variable region.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Region          23. .31
FT                   /note= "Kabat complementarity determining region (CDR)"
FT   Region          31. .35
FT                   /note= "Chothia CDR"
FT   Region          50. .66
FT                   /note= "Kabat/Chothia CDR"
FT   Region          96. .113
FT                   /note= "Kabat/Chothia CDR"
XX
PN   WO2004058190-A2.
XX
PD   15-JUL-2004.
XX
PF   23-DEC-2003; 2003WO-US041367.
XX
PR   23-DEC-2002; 2002US-0436147P.
XX
PA   (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI   Shelton DL;
XX
DR   WPI; 2004-525789/50.
XX
PT   Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT   individual comprises administering to the individual an amount of an anti
PT   -trkC agonist antibody.
XX
PS   Disclosure; Page 24; 68pp; English.
XX
CC   The present invention relates to a method for treating taxol-induced
CC   sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC   method comprises administering to the individual anti-trkC agonist
CC   antibody, which binds an epitope in domain 4 of human trk C. The present
CC   sequence is the heavy chain variable region of the anti-trkC agonist
CC   antibody.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 658;  DB 1;  Length 123;
  Best Local Similarity   100.0%;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60

Qy         61 NEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARKYYYGNTRRSWYFDVWGQGTTV 120
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 NEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARKYYYGNTRRSWYFDVWGQGTTV 120

Qy         121 TVS 123
                |||
Db         121 TVS 123

<!--EndFragment-->
```

<!--StartFragment-->RESULT 1
ADQ31357 SEQ ID No. 2
ID ADQ31357 standard; protein; 113 AA.
XX
AC ADQ31357;
XX
DT 07-OCT-2004 (first entry)
XX
DE Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
XX
KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
KW variable region.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Region 24. .38
FT /note= "Kabat/ Chothia complementarity determining region
FT (CDR)"
FT Region 54. .60
FT /note= "Kabat/ Chothia CDR"
FT Region 93. .101
FT /note= "Kabat/ Chothia CDR"
XX
PN WO2004058190-A2.
XX
PD 15-JUL-2004.
XX
PF 23-DEC-2003; 2003WO-US041367.
XX
PR 23-DEC-2002; 2002US-0436147P.
XX
PA (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI Shelton DL;
XX
DR WPI; 2004-525789/50.
XX
PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT individual comprises administering to the individual an amount of an anti
PT -trkC agonist antibody.
XX
PS Disclosure; Page 24; 68pp; English.
XX
CC The present invention relates to a method for treating taxol-induced
CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC method comprises administering to the individual anti-trkC agonist
CC antibody, which binds an epitope in domain 4 of human trk C. The present
CC sequence is the light chain variable region of the anti-trkC agonist
CC antibody.
XX
SQ Sequence 113 AA;

Query Match 100.0%; Score 581; DB 1; Length 113;
Best Local Similarity 100.0%;
Matches 113; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 DIQMTQSPSSLSASVGDRVTITCRASESIDNYGISFLAWYQQKPGKAPKLLIYAASNRGS 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 DIQMTQSPSSLSASVGDRVTITCRASESIDNYGISFLAWYQQKPGKAPKLLIYAASNRGS 60

Qy         61 GVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSKTVPRTFGQGTKLEIKRT 113
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db          61 GVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSKTVPRTFGQGTKLEIKRT 113

<!--EndFragment-->
```

<!--StartFragment-->RESULT 3
ADQ31356

SEQ ID No. 4

ID   ADQ31356 standard; protein; 123 AA.
XX
AC   ADQ31356;
XX
DT   07-OCT-2004 (first entry)
XX
DE   Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
XX
KW   Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW   allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
KW   variable region.
XX
OS   Synthetic.
XX
FH   Key   Location/Qualifiers
FT   Region   23. .31
FT   /note= "Kabat complementarity determining region (CDR)"
FT   Region   31. .35
FT   /note= "Chothia CDR"
FT   Region   50. .66
FT   /note= "Kabat/Chothia CDR"
FT   Region   96. .113
FT   /note= "Kabat/Chothia CDR"
XX
PN   WO2004058190-A2.
XX
PD   15-JUL-2004.
XX
PF   23-DEC-2003; 2003WO-US041367.
XX
PR   23-DEC-2002; 2002US-0436147P.
XX
PA   (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI   Shelton DL;
XX
DR   WPI; 2004-525789/50.
XX
PT   Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT   individual comprises administering to the individual an amount of an anti
PT   -trkC agonist antibody.
XX
PS   Disclosure; Page 24; 68pp; English.
XX
CC   The present invention relates to a method for treating taxol-induced
CC   sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC   method comprises administering to the individual anti-trkC agonist
CC   antibody, which binds an epitope in domain 4 of human trk C. The present
CC   sequence is the heavy chain variable region of the anti-trkC agonist
CC   antibody.
XX
SQ   Sequence 123 AA;

  Query Match   100.0%; Score 10; DB 1; Length 123;
  Best Local Similarity   100.0%;
  Matches   10; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 GYTFTSYRIH 10
              ||||||||||
Db   26 GYTFTSYRIH 35
<!--EndFragment-->

<!--StartFragment-->RESULT 3
ADQ31356

SEQ ID No. 5

ID ADQ31356 standard; protein; 123 AA.
XX
AC ADQ31356;
XX
DT 07-OCT-2004 (first entry)
XX
DE Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
XX
KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
KW variable region.
XX
OS Synthetic.
XX
FH Key   Location/Qualifiers
FT Region   23. .31
FT   /note= "Kabat complementarity determining region (CDR)"
FT Region   31. .35
FT   /note= "Chothia CDR"
FT Region   50. .66
FT   /note= "Kabat/Chothia CDR"
FT Region   96. .113
FT   /note= "Kabat/Chothia CDR"
XX
PN WO2004058190-A2.
XX
PD 15-JUL-2004.
XX
PF 23-DEC-2003; 2003WO-US041367.
XX
PR 23-DEC-2002; 2002US-0436147P.
XX
PA (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI Shelton DL;
XX
DR WPI; 2004-525789/50.
XX
PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT individual comprises administering to the individual an amount of an anti
PT -trkC agonist antibody.
XX
PS Disclosure; Page 24; 68pp; English.
XX
CC The present invention relates to a method for treating taxol-induced
CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC method comprises administering to the individual anti-trkC agonist
CC antibody, which binds an epitope in domain 4 of human trk C. The present
CC sequence is the heavy chain variable region of the anti-trkC agonist
CC antibody.
XX
SQ Sequence 123 AA;

  Query Match   100.0%; Score 17; DB 1; Length 123;
  Best Local Similarity   100.0%;
  Matches   17; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 EIYPSNARTNYNEKFKS 17
              |||||||||||||||||
Db   50 EIYPSNARTNYNEKFKS 66

<!--EndFragment-->

<!--StartFragment-->RESULT 3
ADQ31356

SEQ ID No. 6

```
ID   ADQ31356 standard; protein; 123 AA.
XX
AC   ADQ31356;
XX
DT   07-OCT-2004  (first entry)
XX
DE   Anti-trkC agonist antibody heavy chain variable region, SEQ ID 1.
XX
KW   Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW   allodynia; cancer; anti-trkC agonist antibody; trk C; heavy chain;
KW   variable region.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Region          23. .31
FT                   /note= "Kabat complementarity determining region (CDR)"
FT   Region          31. .35
FT                   /note= "Chothia CDR"
FT   Region          50. .66
FT                   /note= "Kabat/Chothia CDR"
FT   Region          96. .113
FT                   /note= "Kabat/Chothia CDR"
XX
PN   WO2004058190-A2.
XX
PD   15-JUL-2004.
XX
PF   23-DEC-2003; 2003WO-US041367.
XX
PR   23-DEC-2002; 2002US-0436147P.
XX
PA   (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI   Shelton DL;
XX
DR   WPI; 2004-525789/50.
XX
PT   Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT   individual comprises administering to the individual an amount of an anti
PT   -trkC agonist antibody.
XX
PS   Disclosure; Page 24; 68pp; English.
XX
CC   The present invention relates to a method for treating taxol-induced
CC   sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC   method comprises administering to the individual anti-trkC agonist
CC   antibody, which binds an epitope in domain 4 of human trk C. The present
CC   sequence is the heavy chain variable region of the anti-trkC agonist
CC   antibody.
XX
SQ   Sequence 123 AA;

  Query Match             100.0%;  Score 15;  DB 1;  Length 123;
  Best Local Similarity   100.0%;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 KYYYGNTRRSWYFDV 15
              |||||||||||||||
Db         99 KYYYGNTRRSWYFDV 113
```

<!--EndFragment-->

<!--StartFragment-->RESULT 3
ADQ31357

SEQ ID No. 7

ID   ADQ31357 standard; protein; 113 AA.
XX
AC   ADQ31357;
XX
DT   07-OCT-2004 (first entry)
XX
DE   Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
XX
KW   Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW   allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
KW   variable region.
XX
OS   Synthetic.
XX
FH   Key   Location/Qualifiers
FT   Region   24. .38
FT   /note= "Kabat/ Chothia complementarity determining region
FT   (CDR)"
FT   Region   54. .60
FT   /note= "Kabat/ Chothia CDR"
FT   Region   93. .101
FT   /note= "Kabat/ Chothia CDR"
XX
PN   WO2004058190-A2.
XX
PD   15-JUL-2004.
XX
PF   23-DEC-2003; 2003WO-US041367.
XX
PR   23-DEC-2002; 2002US-0436147P.
XX
PA   (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI   Shelton DL;
XX
DR   WPI; 2004-525789/50.
XX
PT   Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT   individual comprises administering to the individual an amount of an anti
PT   -trkC agonist antibody.
XX
PS   Disclosure; Page 24; 68pp; English.
XX
CC   The present invention relates to a method for treating taxol-induced
CC   sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC   method comprises administering to the individual anti-trkC agonist
CC   antibody, which binds an epitope in domain 4 of human trk C. The present
CC   sequence is the light chain variable region of the anti-trkC agonist
CC   antibody.
XX
SQ   Sequence 113 AA;

  Query Match   100.0%; Score 15; DB 1; Length 113;
  Best Local Similarity   100.0%;
  Matches   15; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 RASESIDNYGISFLA 15
              |||||||||||||||
Db   24 RASESIDNYGISFLA 38

<!--EndFragment-->

<!--StartFragment-->RESULT 4
ADQ31357

SEQ ID No. 8

ID ADQ31357 standard; protein; 113 AA.
XX
AC ADQ31357;
XX
DT 07-OCT-2004 (first entry)
XX
DE Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
XX
KW Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
KW variable region.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Region 24. .38
FT /note= "Kabat/ Chothia complementarity determining region
FT (CDR)"
FT Region 54. .60
FT /note= "Kabat/ Chothia CDR"
FT Region 93. .101
FT /note= "Kabat/ Chothia CDR"
XX
PN WO2004058190-A2.
XX
PD 15-JUL-2004.
XX
PF 23-DEC-2003; 2003WO-US041367.
XX
PR 23-DEC-2002; 2002US-0436147P.
XX
PA (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI Shelton DL;
XX
DR WPI; 2004-525789/50.
XX
PT Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT individual comprises administering to the individual an amount of an anti
PT -trkC agonist antibody.
XX
PS Disclosure; Page 24; 68pp; English.
XX
CC The present invention relates to a method for treating taxol-induced
CC sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC method comprises administering to the individual anti-trkC agonist
CC antibody, which binds an epitope in domain 4 of human trk C. The present
CC sequence is the light chain variable region of the anti-trkC agonist
CC antibody.
XX
SQ Sequence 113 AA;

Query Match 100.0%; Score 7; DB 1; Length 113;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AASNRGS 7
|||||||
Db 54 AASNRGS 60
<!--EndFragment-->

<!--StartFragment-->RESULT 3
ADQ31357

SEQ ID No. 9

```
ID   ADQ31357 standard; protein; 113 AA.
XX
AC   ADQ31357;
XX
DT   07-OCT-2004  (first entry)
XX
DE   Anti-trkC agonist antibody light chain variable region, SEQ ID 2.
XX
KW   Neuroprotective; Analgesic; Cytostatic; taxol-induced sensory neuropathy;
KW   allodynia; cancer; anti-trkC agonist antibody; trk C; light chain;
KW   variable region.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Region          24. .38
FT                   /note= "Kabat/ Chothia complementarity determining region
FT                   (CDR)"
FT   Region          54. .60
FT                   /note= "Kabat/ Chothia CDR"
FT   Region          93. .101
FT                   /note= "Kabat/ Chothia CDR"
XX
PN   WO2004058190-A2.
XX
PD   15-JUL-2004.
XX
PF   23-DEC-2003; 2003WO-US041367.
XX
PR   23-DEC-2002; 2002US-0436147P.
XX
PA   (RINA-) RINAT NEUROSCIENCE CORP.
XX
PI   Shelton DL;
XX
DR   WPI; 2004-525789/50.
XX
PT   Treating taxol-induced sensory neuropathy (e.g. allodynia) in an
PT   individual comprises administering to the individual an amount of an anti
PT   -trkC agonist antibody.
XX
PS   Disclosure; Page 24; 68pp; English.
XX
CC   The present invention relates to a method for treating taxol-induced
CC   sensory neuropathy (e.g. allodynia) or cancer in an individual. The
CC   method comprises administering to the individual anti-trkC agonist
CC   antibody, which binds an epitope in domain 4 of human trk C. The present
CC   sequence is the light chain variable region of the anti-trkC agonist
CC   antibody.
XX
SQ   Sequence 113 AA;

  Query Match             100.0%;  Score 9;  DB 1;  Length 113;
  Best Local Similarity   100.0%;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 QQSKTVPRT 9
              |||||||||
Db         93 QQSKTVPRT 101
```

<!--EndFragment-->

<!--StartFragment-->RESULT 2
US-10-549-441-1

SEQ ID No. 1

; Sequence 1, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 123
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-549-441-1

  Query Match   100.0%; Score 658; DB 5; Length 123;
  Best Local Similarity   100.0%;
  Matches 123; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRIHWVRQAPGQGLEWMGEIYPSNARTNY 60

Qy         61 NEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARKYYYGNTRRSWYFDVWGQGTTV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 NEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARKYYYGNTRRSWYFDVWGQGTTV 120

Qy        121 TVS 123
              |||
Db        121 TVS 123
```

<!--EndFragment-->

<!--StartFragment-->RESULT 2
US-10-549-441-2

SEQ ID No. 2

; Sequence 2, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 113
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-549-441-2

  Query Match   100.0%; Score 581; DB 5; Length 113;
  Best Local Similarity   100.0%;
  Matches 113; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 DIQMTQSPSSLSASVGDRVTITCRASESIDNYGISFLAWYQQKPGKAPKLLIYAASNRGS 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 DIQMTQSPSSLSASVGDRVTITCRASESIDNYGISFLAWYQQKPGKAPKLLIYAASNRGS 60

Qy         61 GVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSKTVPRTFGQGTKLEIKRT 113
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSKTVPRTFGQGTKLEIKRT 113
```

<!--EndFragment-->

SEQ ID No. 4

```
<!--StartFragment-->RESULT 1
US-10-549-441-3
; Sequence 3, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
;  APPLICANT: Shelton, David L.
;  TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
;  TITLE OF INVENTION:  DISORDER
;  FILE REFERENCE: 514712001600
;  CURRENT APPLICATION NUMBER: US/10/549,441
;  CURRENT FILING DATE:  2005-09-16
;  PRIOR APPLICATION NUMBER: PCT/US2004/008865
;  PRIOR FILING DATE: 2004-03-22
;  PRIOR APPLICATION NUMBER: US 60/456,648
;  PRIOR FILING DATE: 2003-03-20
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 13
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-549-441-3

  Query Match             100.0%;  Score 10;  DB 5;  Length 13;
  Best Local Similarity   100.0%;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 GYTFTSYRIH 10
              ||||||||||
Db          4 GYTFTSYRIH 13
<!--EndFragment-->
```

SEQ ID No. 5

```
<!--StartFragment-->RESULT 1
US-10-549-441-4
; Sequence 4, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
;  APPLICANT: Shelton, David L.
;  TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
;  TITLE OF INVENTION:  DISORDER
;  FILE REFERENCE: 514712001600
;  CURRENT APPLICATION NUMBER: US/10/549,441
;  CURRENT FILING DATE:  2005-09-16
;  PRIOR APPLICATION NUMBER: PCT/US2004/008865
;  PRIOR FILING DATE: 2004-03-22
;  PRIOR APPLICATION NUMBER: US 60/456,648
;  PRIOR FILING DATE: 2003-03-20
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
;   LENGTH: 17
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-549-441-4

  Query Match             100.0%;  Score 17;  DB 5;  Length 17;
  Best Local Similarity   100.0%;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EIYPSNARTNYNEKFKS 17
              |||||||||||||||||
Db          1 EIYPSNARTNYNEKFKS 17
<!--EndFragment-->
```

SEQ ID No. 6

```
<!--StartFragment-->RESULT 1
US-10-549-441-5
; Sequence 5, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
;  APPLICANT: Shelton, David L.
;  TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
;  TITLE OF INVENTION:  DISORDER
;  FILE REFERENCE: 514712001600
;  CURRENT APPLICATION NUMBER: US/10/549,441
;  CURRENT FILING DATE:  2005-09-16
;  PRIOR APPLICATION NUMBER: PCT/US2004/008865
;  PRIOR FILING DATE: 2004-03-22
;  PRIOR APPLICATION NUMBER: US 60/456,648
;  PRIOR FILING DATE: 2003-03-20
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-549-441-5

  Query Match             100.0%;  Score 15;  DB 5;  Length 18;
  Best Local Similarity   100.0%;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 KYYYGNTRRSWYFDV 15
              |||||||||||||||
Db          4 KYYYGNTRRSWYFDV 18
<!--EndFragment-->
```

<!--StartFragment-->RESULT 1
US-10-549-441-6
; Sequence 6, Application US/10549441 SEQ ID No. 7
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 15
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-549-441-6

Query Match 100.0%; Score 15; DB 5; Length 15;
Best Local Similarity 100.0%;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RASESIDNYGISFLA 15
||||||||||||||||
Db 1 RASESIDNYGISFLA 15
<!--EndFragment-->

<!--StartFragment-->RESULT 1
US-10-549-441-7

SEQ ID No. 8

; Sequence 7, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-549-441-7

  Query Match   100.0%; Score 7; DB 5; Length 7;
  Best Local Similarity   100.0%;
  Matches   7; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 AASNRGS 7
              |||||||
Db   1 AASNRGS 7
<!--EndFragment-->

<!--StartFragment-->RESULT 1
US-10-549-441-8
; Sequence 8, Application US/10549441
; Publication No. US20070014786A1
; GENERAL INFORMATION:
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: METHODS FOR TREATING TAXOL-INDUCED GUT
; TITLE OF INVENTION: DISORDER
; FILE REFERENCE: 514712001600
; CURRENT APPLICATION NUMBER: US/10/549,441
; CURRENT FILING DATE: 2005-09-16
; PRIOR APPLICATION NUMBER: PCT/US2004/008865
; PRIOR FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US 60/456,648
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
US-10-549-441-8

SEQ ID No. 9

  Query Match   100.0%; Score 9; DB 5; Length 9;
  Best Local Similarity   100.0%;
  Matches   9; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 QQSKTVPRT 9
              |||||||||
Db   1 QQSKTVPRT 9
<!--EndFragment-->